Objectives: To review the indications, contraindications and efficacy of vaccination in some special situations: immunosuppression, prematurity, pregnancy and post-exposure situations. Summary of the findings: Some special situations, such as immunosuppression, prematurity, pregnancy and exposure to infectious diseases increased the risk of diseases or adverse post-vaccination events. In these situations, special vaccines or special vaccination schedules are indicated, or vaccines should be postponed or even forbidden. In general, toxoid or inactivated vaccines can be used, considering the possibility of insufficient immune response. For immunosuppressed patients, in accordance with the type of immunosuppression, live virus or bacterial vaccines should be avoided, because of the risk of vaccine agent spread. Immunization should include not only the patient, but his/her home and day-care contacts as well.
Introduction
Generally speaking, vaccination schedules are meant for healthy individuals under normal life conditions. Some special situations, however, place individuals at greater risk of becoming ill or presenting with adverse postvaccine events and may require specific vaccines or vaccine schemes, or even indicate postponement or contraindication of vaccination.
As follows, we shall discuss some special situations in which the usual vaccine scheme may be modified, postponed or reinforced.
Pre-term newborns
Premature newborns, irrespective of gestational age and birth weight, may receive vaccines in the same scheme and doses used for full term children, except for hepatitis B vaccine. 1 Immunization with hepatitis B vaccine at birth in premature newborns with birth weight under 2,000 g may determine low serum conversion rates; an immunization schedule started at 30 or more days of life determines a response similar to that obtained in full-term newborns with birth weight over 2,000 g. 1, 2 Pre-term newborns born to HbsAg-positive mothers or those born to mothers whose HbsAg status is unknown must receive vaccine against hepatitis B and specific hepatitis B immunoglobulin (HBIG) within 12 hours of birth; if the birth weight is under 2,000 g, another three doses of the vaccine must be administered, the first of these at the chronological age of 1 month.
Considering the possibility of prolonged hospitalizations and the risk of invasive bacterial diseases, it is advisable that pre-term newborns should receive pneumococcal conjugate and meningococcal conjugate vaccines, as from 2 months of age; the immunogenicity, efficacy and safety of these vaccines is similar for term and pre-term newborns. 3, 4 There are no studies yet about the use of rotavirus vaccine in premature infants.
Yearly influenza immunization in autumn, as from the age of 6 months, is particularly important for premature infants with chronic pulmonary diseases. 1 Vaccinating family members and other persons that care for the baby is useful, mainly for children under the age of 6 months.
Although there is no absolute contra-indication, the Programa Nacional de Imunizações (Brazilian National Immunization Program) postpones the application of BCG vaccine in newborns weighing less than 2,000 g at birth. 5 
Natural breastfeeding and vaccination
No vaccine is contra-indicated or should be postponed in breastfed children the habitual vaccination scheme must be used. There is also no contra-indication of vaccination for breastfeeding mothers, as the majority of live vaccine agents are not excreted in mothers milk.
Although attenuated vaccine virus may be transmitted to the nursing infant through mothers milk in the case of rubella vaccine, this does not determine additional risk for the child. 6 
Vaccination of pregnant women
It is desirable for a woman to be properly immunized before pregnancy starts, but in the event that it is necessary to vaccinate a pregnant woman, the medical, legal and social risks of vaccination at this specific time of life must be assessed, with a view to protecting the pregnant woman and the newborn. 7 Studies have been conducted to seek vaccines which, when applied to pregnant women, are able to induce protection against common and serious diseases in the neonatal period, such as infections by Streptococcus agalactiae and Streptococcus pneumoniae. 7, 8 When indicated, vaccines containing inactivated viruses or bacteria and toxoid may be applied in pregnant women without risks to the fetus. 9 However, live vaccines are contraindicated during gestation, and women at a fertile age must be guided to avoid pregnancy for 4 week after vaccination with live virus vaccines. 7 susceptible pregnant women were inadvertently vaccinated against rubella and it was possible to collect blood samples from 580 newborns of these susceptible women. 10 The congenital infection rate in these newborns was 4.7% (27/ 580), but no child presented with clinical manifestations of the congenital rubella syndrome. Greater risk of prematurity and low birth weight was however, observed among the infected newborn in comparison with non-infected newborns of susceptible mothers and newborns of immune mothers vaccinated during gestation. 10 Vaccination with live vaccines to the home contacts of pregnant mothers does not cause any risk to the pregnant women. In situations in which the risk of acquiring disease is greater (for the pregnant mother and/or for the fetus) than the potential risk of the vaccine to the fetus, live oral poliomyelitis vaccines, yellow fever and rabies vaccines may be applied to pregnant women. 1, 11, 12 Two vaccines should routinely be offered to pregnant women: tetanus vaccine (with the purpose of preventing neonatal tetanus through passive transplacental antibody passage) and influenza vaccine. 7, 11, 12 Pregnant women that have completed the tetanus primary immunization schedule must receive a booster dose during pregnancy, in the event that the interval between the last dose of the vaccine and pregnancy is longer than 5 years; nonimmunized pregnant women must receive three doses of the vaccine starting as early as possible in the pregnancy; partially vaccinated pregnant women must complete the immunization schedule during gestation. 5 The interval between the first two doses is 2 months, and between the second and third doses, 6 months. If there is no time to apply the three doses of the vaccine during pregnancy, the second dose must be applied at the latest 20 days before the probable date of birth. Every time there is indication of anti-tetanus vaccination, the combined tetanusdiphtheria toxoid vaccine (dT) may be applied to take advantage of the opportunity to protect against diphtheria, since this disease still exists in an endemic form in the country.
Influenza vaccine is recommended for healthy pregnant women with more than 14 weeks of gestation, in the months preceding the influenza season, to diminish the increased risk of severe forms of influenza when pregnant women are hospitalized for this disease; the vaccine is safe throughout pregnancy. 12, 13 Hepatitis A and B vaccines may be applied to susceptible pregnant women who are exposed during gestation. 1, 11 Pneumococcal vaccine may be applied to pregnant women with risk of severe disease caused by S. pneumoniae. 1 Inactivated polio vaccine (IPV), meningococcal vaccine (conjugate or polysaccharide), oral attenuated or inactivated typhoid fever vaccine can be applied during gestation under special epidemiological conditions (epidemics or journeys to areas where there is increased risk of acquiring the disease). 11, 12 Taking advantage of the puerperal period to vaccinate women susceptible to rubella, measles and other preventable infections by the application of attenuated live virus vaccines is a measure that has great impact on public health.
Vaccinating the immunodeficient child
In the last 3 decades, there has been a considerable which may last for up to 4 weeks. 1 Other live virus vaccines, such as measles/rubella/mumps vaccine, and yellow fever vaccine are also contra-indicated for children with T cell immunodeficiency, but there is no contraindication for applying these vaccines to these patients household contacts, as the vaccine virus is not disseminated from the vaccinated individual. 1 Attenuated live vaccines against measles, mumps and rubella may be considered for children with slight antibody immunodeficiency. 16 The varicella vaccine may be applied in children with antibody immunodeficiency, but is contra-indicated in those with cellular immunodeficiency. 17 Vaccinating immunodeficient childrens susceptible household contacts, however, is an efficient way to diminish the risk of contact for patients with altered immune response. In the event of post-vaccine cutaneous rash development, the vaccinated individuals must not come into contact with the immunosuppressed patient.
Yearly influenza immunization (before winter) is safe and is indicated in congenitally immunodeficient patients who have greater influenza morbidity and mortality. 13 The vaccine must also be offered to the patients household contacts, thereby reducing the risk of transmission.
Children with complement deficiency may receive all the vaccines in the routine calendar; there is specific indication for immunization against meningococci, Haemophilus influenzae type b (Hib) and pneumococci. 18 Children with phagocytosis defects must not receive BCG vaccine, but they may receive the other vaccines in the routine calendar. 19 The protective response obtained with immunization of those congenital immune deficiency children may be inadequate: the antibody titers obtained may be insufficient, and they may drop more quickly than usual. Thus, even though vaccinated, these patients may remain susceptible to infectious diseases, which make it advisable to perform serologic tests to assess the antibody levels obtained after vaccination; additional or higher doses of vaccines may be necessary and even so, the response obtained may not be optimal. Taking all this into consideration, in the event of exposure to infectious diseases, these patients must be considered susceptible and passive immunization, if available, must be indicated. 16, 17 Vaccinating the child with cancer
The cancer patient must be strictly assessed to verify the immunosuppression conditions dependent on the disease itself, the therapy that the patient is or was submitted to and the risks of the disease one wants to prevent. Live vaccines are formally contra-indicated, and inactivated, sub-unitary, recombining, polysaccharide and toxoid vaccines may be applied, although it is known that the vaccine efficacy may be substantially reduced. The immune response is usually adequate three months to 1
year after chemotherapy has been suspended. When the baseline disease is in remission, and immunosuppressive therapy has been suspended for a period longer than 3 months, the use of live virus vaccines may be considered. 1, 16 Under the following conditions, the vaccine against varicella may be applied in patients with acute lymphoid leukemia: 1, 16, 17 remission for at least 1 year, peripheral blood lymphocyte and platelet counts higher than 700/mm 3 and 100,000/mm 3 , respectively. Two doses should be applied with an interval of 8 weeks between them.
The influenza vaccine 1 must be applied at least 3 to 4 weeks after chemotherapy has been interrupted and when the peripheral granulocyte and lymphocyte counts are higher than 1,000 cells/mm 3 . The recommendations for vaccinating the contacts are the same as those made for congenital immunodeficiencies.
Children with cancer are at greater risk of developing invasive Hib disease than immunocompetent children. The more intense and prolonged chemotherapy is, the worse the vaccine response is, thus it is advisable for these patients to receive the vaccine as early as possible after diagnosis and preferably before chemotherapy. 16 In spite of the increased risk of developing Pneumococcus invasive disease, the pneumonococcal vaccine may result in sub-optimal protective response in patients with hematologic neoplasias; with the purpose of obtaining protective antibody levels after vaccination, the vaccine must be applied as early as possible after diagnosis, before radiotherapy or chemotherapy begins. 20 Children under the age of 5 years must receive 7-valent conjugate vaccine; children from 2 to 5 years of age that have never been vaccinated should receive two doses of the conjugate vaccine with a 6 to 8 week interval between them, after that, two doses of polysaccharide vaccine: the first dose 6 to 8 weeks after the conjugate vaccine, and the second dose 3 to 5 years after the first polysaccharide vaccine. 20 Children who have had the complete vaccine schedule for their age must receive a booster dose of the conjugate vaccine and two doses of the polysaccharide vaccine with the same interval as before. 20 Children aged between 5 and 10 years receive two doses of polysaccharide vaccine with an interval of 3 years between the doses; over the age of 10 years, they require two doses of the vaccine with an interval of 5 years between doses. 20 The antibody titers against tetanus, diphtheria and poliomyelitis may be low in cancer patients submitted to chemotherapy; when chemotherapy ends, booster doses of these vaccines must be applied in children and adolescents who have completed the basic vaccination schedule against these diseases.
Vaccination of children with Hodgkins disease
Patients with Hodgkins disease may have functional asplenia as a result of the disease or be splenectomized as part of the treatment, and are thus susceptible to disseminated pneumococcal infections. Pneumococcal vaccine must be applied as previously described. The response is better if the vaccine is applied 10 to 14 days before splenectomy or chemotherapy. 16, 19 Vaccine applied during or soon after chemotherapy offers the worst results, but the ability to respond with antibody production is rapidly recovered, and may be considered reasonable 3 months after chemotherapy ceases. Patients who receive vaccine during chemotherapy must receive an additional dose 3 months after chemotherapy ends. 1 In these patients, there is also increased risk of developing invasive Hib diseases, and the conjugate vaccine against this agent must be applied. Varicella vaccine has been used in kidney transplant children with encouraging results, 25 but it has still not been tested in bone marrow transplant recipients. The use of specific varicella-zoster (VZIG) immunoglobulin is indicated for susceptible patients who are exposed to the disease. 1 BCG vaccine must not be applied to patients submitted to bone marrow or solid organ transplants.
Vaccination of the child receiving corticosteroid therapy
The dose and duration of corticotherapy required to induce immunosuppression in immunocompetent children and adults is still under discussion. In addition to the dose, BCG vaccine is recommended at birth in countries with high risk for tuberculosis, such as Brazil, but it is contra-indicated in patients who already present with immunosuppression or clinical signs of the disease. 31 There are still no studies that prove the efficacy and safety of BCG vaccine for protection against tuberculosis in HIV infected children, which makes it difficult to assess the risks and benefits of its application. Although clinical experience has shown good safety of the vaccine in asymptomatic children, regional lymphadenitis may occur, and cases have been described of dissemination of the vaccine bacillus in these children. 32 As the vaccine contains attenuated live mycobacteria, infected children who present with immune reconstitution after HAART has been instituted, may have infection by BCG reactivated long after its application; this reactivation is manifested as abscesses at the vaccine site or in regional lymph nodes. 33 The tuberculin test performed 6 to 12 months after BCG vaccination was not reactive in over 90% of the Brazilian HIV-infected children. 34 OPV can be applied to HIV-infected children, 35 but preference must be given to IPV, not only for the patients, but for their family members and home contacts as well.
In Brazil it is possible to apply IPV in the Special
Immunobiology Referral Centers (CRIE Centros de Referência para Imunobiológicos Especiais). Two cases of post-vaccine paralytic poliomyelitis were described in HIV infected children in Romania and Zimbabwe, but it is not clear whether the occurrence of the paralytic accident in these children was greater than that expected in the general population not infected by HIV. 28, 29, 36 Symptomatic HIV-infected children or those with severe immunodeficiency must receive only IPV. 31 Children born to HIV-infected mothers may present reduced placental transfer of antibodies against measles, and be susceptible to natural infection soon after birth. 37 The antibody response after vaccination may be diminished, particularly among symptomatic children with immunosuppression. 37, 38 Measles vaccine applied in isolation or in association with rubella and mumps vaccines are safe, and its use has not been associated with greater frequency of adverse events, even in symptomatic individuals. 36 Two cases of measles pneumonitis after vaccination have been described: one adult died 24 and one child recovered. 39 ) and who present a T CD4+ lymphocyte percentage higher than or equal to 25%. 17, 31, 43 Children and adults susceptible to varicella who are exposed to a household, school or in-hospital contact case of varicella must receive VZIG intramuscularly at a dose of 125 U for each 10 kg of weight, with a maximum of 625 U, as quickly as possible after contact, at most within the first 96 hours. 1, 41 The antibody production response against tetanus, diphtheria and Hib would appear to be adequate after primary vaccination in children receiving powerful antiretroviral therapy; 44 31, 40 In Brazil, the hepatitis A vaccine is not available to all HIV-infected children; it must be applied to susceptible individuals who present with hepatopathy in a two-dose schedule with an interval of 6 months between them. 40 Research conducted at UNIFESP with children and adolescents exposed to HIV revealed that the prevalence of individuals susceptible to hepatitis A among adolescents is greater than in the non-infected population 48 and that the vaccine is safe and efficient, protecting 100% of the vaccinated HIV-infected children (without severe immunosuppression). 49 Considering that children with 
Post-exposure vaccination
Infectious disease control includes measures that aim to control the dissemination of disease in the community or in the home. In addition to compulsory notification of some diseases to the epidemiologic surveillance system in order to set control measures in motion, steps must be taken to isolate the patient and prevent or attenuate the disease with the use of antimicrobial agents, immunoglobulin or serums and vaccines.
Here we shall deal with the infectious diseases for which the use of vaccines may prevent infection and the disease, even after exposure.
Mumps
The vaccine against mumps must be administered soon after exposure in unvaccinated exposed children, although there is no evidence that the vaccine prevents the disease from appearing. 50 
Pertussis (whooping cough)
Non-immunized children under the age of 7 years, who Previously immunized children over the age of 7 years must receive a booster dose of dT, provided that they have not received diphtheria vaccine in the last 5 years.
Hepatitis A
The hepatitis A vaccine has been successfully used in post-exposure prophylaxis to control outbreaks and in home and day care center contacts. [53] [54] [55] It must be applied as soon as possible after contact. The use of human immunoglobulin is efficient in post-exposure prophylaxis, when applied up to 2 weeks after contact. 53 
Hepatitis B
Post-exposure prophylaxis must be considered for sexual contacts, home contacts and exposure to blood and derivatives. Perinatal HBV transmission can be prevented in 95% of the newborns to HBsAg+ mothers by active and passive immuno-prophylaxis. 56 Newborns to HBsAg+ mothers must receive hyperimmune human immunoglobulin (HBIG) and vaccine up to 12 hours after delivery; vaccine and HBIG must be administered in different anatomic sites. HBIG must be administered at a dose of 0.5 mL, and the vaccine schedule must be completed with additional doses of the vaccine at 30 days and 6 months; premature newborns weighing under 2,000 g must receive a fourth dose of the vaccine.
Newborns to mothers with unknown serology for hepatitis B must also receive vaccine and immunoglobulin soon after birth. 56 Children under the age of 12 months who do not receive vaccination against hepatitis B and who are in contact at home with HBsAg+ patients must receive HBIG and vaccine; if one or two doses of the vaccine have already been given, the vaccine schedule must be completed. 56 In sexual exposure, the informer must receive HBIG at the dose of 0.06 mL/kg (maximum of 5 mL), up to 14 days from contact and also start a vaccine schedule (0, 1 and 6 months).
Prophylaxis in situations of percutaneous accidents with possibly infected blood depends on the exposed persons vaccine status. Unvaccinated persons must receive HBIG and vaccine; partially vaccinated persons must complete the vaccine scheme. 56 
Meningococci
Careful clinical surveillance and chemo-prophylaxis, preferably in the first 24 hours after exposure to cases of meningococcemia, are mandatory for individuals of any age. 57 The immunization with meningococcal vaccine may be done concurrently with chemo-prophylaxis in outbreak situations, when the serogroup is known and there is an efficient vaccine available, since secondary cases may occur several weeks after the beginning of the index case symptoms. 57 
Measles
The measles vaccine is useful to avoid the appearance of the disease, if administered within 72 hours after contact with a measles case. Therefore, this measure should be implemented as soon as possible. 1 
Tetanus
Non-immunized, or incompletely immunized individuals with tetanogenic injuries must receive a dose of the tetanus vaccine, and additional doses must be offered to complete the primary immunization scheme. 5 The need for the simultaneous use of passive immunization depends on the type of injury, the number of doses of the vaccine already received, and the time elapsed since the last dose of the vaccine. 5 
Rabies
In case of exposure to the rabies virus, immediate and careful local treatment must be followed by passive immunoprophylaxis (anti-rabies immunoglobulin) and active immunoprophylaxis (vaccine). The vaccine (obtained in cellular culture) must be applied preferably in the first 24 hours after exposure, but considering the severity of the disease, it must be applied at any time after exposure 58 in five doses on days 0, 3, 7, 14 and 28. 
